Ab­b­Vie’s $10B Ro­va-T play ends in one last fail­ure — R&D team shuts it all down

Ab­b­Vie’s Ro­va-T has failed its last clin­i­cal tri­al.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.